8-K: Schrödinger Reports Mixed Q1 2024 Results: Software Growth Offsets Drug Discovery Decline, Pipeline Progresses

Schrödinger's Q1 2024 results show a decrease in total revenue due to a large collaboration milestone in the previous year, but software revenue saw a modest increase, and the company's drug pipeline continues to advance.

Summary

• Schrödinger reported a total revenue of $36.6 million for the first quarter of 2024, a decrease from $64.8 million in the same period of 2023.
• This decrease is primarily attributed to a significant collaboration milestone payment that boosted revenue in Q1 2023.
• Software revenue increased by 3.7% to $33.4 million, compared to $32.2 million in the first quarter of 2023, driven by growth in hosted licenses.
• Drug discovery revenue significantly decreased to $3.2 million from $32.6 million in the first quarter of 2023, due to the absence of a large milestone payment.
• The company's software gross margin decreased slightly to 76% from 78% due to higher technology expenses.
• Operating expenses increased to $86.3 million, up from $76.2 million in the first quarter of 2023, primarily due to higher R&D spending.
• Schrödinger reported a net loss of $54.7 million for the quarter, compared to a net income of $129.1 million in the same period last year, which included a $147.3 million gain from a Nimbus sale.
• Non-GAAP net loss was $62.4 million, compared to a non-GAAP net loss of $27.6 million in the first quarter of 2023.
• The company's cash, cash equivalents, restricted cash, and marketable securities totaled approximately $435.7 million as of March 31, 2024, down from $468.8 million at the end of 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive developments in the pipeline and software growth, the significant drop in total revenue and the net loss are concerning. The company's future outlook is cautiously optimistic, but the risks associated with drug development remain.

Positives

• Software revenue experienced growth, indicating continued adoption of the company's platform.
• FDA clearance of the IND application for SGR-3515 marks a significant milestone in the company's proprietary pipeline.
• The launch of LiveDesign Biologics expands the company's offerings in the biologics space.
• The company's computational platform demonstrated its ability to rapidly identify promising drug candidates, as shown with SGR-1505.
• The company has a strong cash position of $435.7 million, providing financial stability for ongoing operations and research.

Negatives

• Total revenue decreased significantly due to the absence of a large collaboration milestone payment from the previous year.
• Drug discovery revenue saw a substantial decline, highlighting the volatility of milestone-based revenue.
• The company reported a net loss of $54.7 million for the quarter, a significant swing from the net income of $129.1 million in the same period last year.
• Operating expenses increased, primarily due to higher R&D costs, impacting profitability.
• Software gross margin decreased slightly due to higher technology expenses.

Risks

• The company's revenue is subject to fluctuations due to the timing of collaboration milestone payments.
• The company's reliance on third-party cloud infrastructure providers poses a potential risk.
• The drug development process is inherently uncertain, with no guarantee of success in clinical trials or regulatory approvals.
• The company's financial performance is subject to fluctuations in the value of the U.S. dollar and foreign currencies.
• The company's ability to retain and hire key personnel is critical to its success.

Future Outlook

Schrödinger maintains its full-year 2024 financial guidance, expecting software revenue growth of 6% to 13%, drug discovery revenue of $30 million to $35 million, and operating expense growth of 8% to 12%. Software revenue for the second quarter of 2024 is expected to range from $31 million to $33 million. Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023.

Management Comments

• Ramy Farid, Ph.D., chief executive officer of Schrödinger, stated that they are excited by the growing appreciation for using computation to drive pharmaceutical innovation.
• Ramy Farid also mentioned that they are pleased with the continued progress of their proprietary pipeline.

Industry Context

The announcement reflects the increasing interest in computational drug discovery within the pharmaceutical industry, with companies like Schrödinger leveraging their platforms to accelerate drug development. The launch of LiveDesign Biologics also highlights the growing importance of computational tools in the biologics space.

Comparison to Industry Standards

• Schrödinger's software revenue growth of 3.7% is modest compared to some high-growth SaaS companies in the tech sector, which can see growth rates of 20% or more, however, it is important to note that the company is in the life sciences sector.
• The significant decrease in drug discovery revenue highlights the inherent variability in this sector, where milestone payments can cause large swings in revenue.
• The company's R&D expenses are substantial, reflecting the high investment required in drug discovery and development, which is typical for biotech companies.
• The company's cash position of $435.7 million is relatively strong, providing a buffer for ongoing operations and research, which is important for a company in the drug discovery space.
• The FDA clearance of the IND application for SGR-3515 is a positive development, but it is important to note that many drug candidates fail in clinical trials, so the risk remains high.

Stakeholder Impact

• Shareholders may be concerned about the decrease in total revenue and the net loss, but encouraged by the progress in the pipeline and software growth.
• Employees may be encouraged by the company's continued investment in research and development.
• Customers may benefit from the company's expanding software platform and drug discovery capabilities.
• Suppliers may see continued business opportunities with the company.
• Creditors may be reassured by the company's strong cash position.

Next Steps

• Schrödinger expects to initiate a Phase 1 clinical study of SGR-3515 in patients with solid tumors in the third quarter of 2024.
• The company will continue to advance the Phase 1 clinical studies of SGR-1505 and SGR-2921, with initial data expected in late 2024 or 2025.
• Schrödinger plans to submit at least one IND in 2025.

Key Dates

Keywords

Computational Drug Discovery, Software Platform, Drug Development, SGR-3515, SGR-1505, SGR-2921, FDA Clearance, Clinical Trials, LiveDesign Biologics, Pharmaceutical Innovation